Higher rate of heart problems with Amgen osteoporosis drug in trial – Reuters

Higher rate of heart problems with Amgen osteoporosis drug in trialReutersMay 21 Amgen Inc and UCB SA on Sunday said their experimental osteoporosis drug, which is awaiting a U.S. approval decision, met the primary and key secondary goals of a late stage study but a higher rate of serious heart problems were reported that …and more

Source:: Osteoporosis Feed

      

Last modified: May 21, 2017